Today's Daily Dose brings you news about Alnylam's new positive efficacy results from its ongoing phase II open-label extension (OLE) study of Lumasiran for the treatment of primary hyperoxaluria type; Five Prime's initial safety data from its phase I clinical trial of FPT155 in patients with advanced solid tumors and Lipocine's much-awaited catalyst.
from RTT - Biotech https://ift.tt/34ISWxs
via IFTTT
No comments:
Post a Comment